Seres Therapeutics, Inc. (MCRB)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.98
- As of
Kresmion compiles this page from MCRB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Seres Therapeutics, Inc. (MCRB): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-04.
See the full MCRB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MCRB on one page. Preview it with sample data, then open it live with a free account.
Preview the MCRB dossierActive events for MCRB
- mediumEarnings below estimates
Q3-2026: Missed consensus by 59.0%, EPS $-1.63 vs $-1.0251 estimate
- mediumEarnings above estimates
Q2-2026: Beat consensus by 32.7%, EPS $-1.50 vs $-2.2287 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 75% of MCRB (2026Q2)
- mediumEarnings above estimates
Q2-2025: Beat consensus by 10.7% - EPS $-2.27 vs $-2.5424 estimate
- mediumEarnings below estimates
Q3-2025: Missed consensus by 28.0% - EPS $0.94 vs $1.3056 estimate
FREE, NO ACCOUNT
Every event on MCRB, as it fires
You are seeing 5 of 7 events recorded on MCRB since 2026-06-02.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
MCRB positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| CITADEL ADVISORS LLC FundCUSIP 81750R201 · 2026Q2 | $83K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MCRB
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
MCRB's 10-Q filed Nov 4, 2026 states:
The principal risks and uncertainties affecting our business include the following: We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on MCRB
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in MCRB on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on MCRB in the last 180 days.
Upstream: SEC EDGAR filings for MCRB
Kresmion, "Seres Therapeutics, Inc. (MCRB) institutional holdings and SEC filings", data as of 2026-11-08, https://kresmion.com/research/MCRB. Upstream data: SEC EDGAR filings for MCRB.
Link to this data (HTML):
<a href="https://kresmion.com/research/MCRB">Seres Therapeutics, Inc. (MCRB) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow MCRB on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to MCRB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.